Kazia Unveils Final Data From Mid-Stage Paxalisib Data In Newly Diagnosed Glioblastoma Patients
Australia-based Kazia Therapeutics Limited (NASDAQ: KZIA) announced
Kazia Announced Final Data From Phase II Clinical Study of Paxalisib in Newly Diagnosed Glioblastoma Confirm Previously Reported Safety and Efficacy Profile
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy in patients with glioblastoma (NCT03522298).
Kazia Therapeutics Announces The GBM AGILE Study In Glioblastoma Has Opened At Sunnybrook Health Sciences Centre In Toronto, Ontario
Kazia Therapeutics Limited ((ASX: KZA, NASDAQ:KZIA), an oncology-focused drug development company, is pleased to inform stakeholders that the GBM AGILE study in glioblastoma (NCT03970447) has opened at Sunnybrook Health
Kazia Therapeutics Named John Friend, MD, as Chief Medical Officer
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr.
Kazia Therapeutics Sponsored Study Titled ‘Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours’ Posted To ClinicalTrials.gov; Study Is Recruiting
https://clinicaltrials.gov/ct2/show/NCT05114668
Kazia Therapeutics Announced it Enrolled First Patient to EVT801 Phase I Clinical Trial
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that it has commenced enrolment to a phase I clinical trial of EVT801, an investigational cancer therapy that Kazia licensed from Evotec SE in April 2021.
Key Points
Maxim Group Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $18
Maxim Group analyst Naureen Quibria initiates coverage on Kazia Therapeutics (NASDAQ:KZIA) with a Buy rating and announces Price Target of $18.
Kazia Therapeutics To Present At LD Micro Main Event From Oct. 12-14
Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA)))), an oncology-focused drug development company, is pleased to announce that CEO, Dr James Garner, will be presenting at the LD Micro Main Event, to be held